Share based payments - Rollforward (Details) |
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
|
Nov. 19, 2025
shares
|
Aug. 07, 2025
shares
|
May 27, 2025
shares
|
Dec. 31, 2025
EquityInstruments
€ / shares
|
Dec. 31, 2024
EquityInstruments
€ / shares
|
Dec. 31, 2023
EquityInstruments
€ / shares
|
Dec. 31, 2022
EquityInstruments
€ / shares
|
|
| Share based payments | |||||||
| Outstanding at the beginning of the year | EquityInstruments | 11,911,109 | 11,472,520 | 10,816,856 | ||||
| Granted during the year | 420,000 | 905,000 | 925,000 | 2,250,000 | 1,381,000 | 1,538,400 | |
| Forfeited during the year | EquityInstruments | (232,299) | (547,911) | (544,676) | ||||
| Exercised during year | EquityInstruments | (61,560) | ||||||
| Expired during the year | EquityInstruments | (700,000) | (394,500) | (276,500) | ||||
| Outstanding at the end of the year | EquityInstruments | 13,228,810 | 11,911,109 | 11,472,520 | ||||
| Exercisable | EquityInstruments | 8,822,812 | 5,182,941 | 5,836,538 | 2,574,218 | |||
| Weighted average exercise price at beginning of the year | € 73.19 | € 77.93 | € 83.12 | ||||
| Granted during the period | 26.86 | 26.87 | 35.53 | ||||
| Forfeited during the year | 55.51 | 72.66 | 80.31 | ||||
| Exercised during the period | 28.75 | ||||||
| Expired during the year | 80.31 | 46.1 | 49 | ||||
| Weighted average exercise price at end of the year | 65.24 | 73.19 | 77.93 | ||||
| Exercisable | € 83.32 | € 107.03 | € 101.93 | € 70.26 | |||